Peng Cheng

机构：Nanyang Medical College · ORCID：0000-0001-9532-1306

发表论文 4 篇 · 总被引 83 次 · h-index 2

代表论文

• A prognostic 3‐long noncoding RNA signature for patients with gastric cancer (2018 · Journal of Cellular Biochemistry · 被引 60)
• Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study (2024 · European Journal of Cancer · 被引 21)
• Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial. (2024 · Journal of Clinical Oncology · 被引 2)
• Early clinical diagnostic value of PGI, PGIIand G-17 in patients with atrophic gastritis and gastric cancer (2018 · Central Plains Medical Journal)